Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Share-based Compensation (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Share-based Compensation for 6 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 26.72% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.0 million through Dec 2025, down 15.7% year-over-year, with the annual reading at $22.0 million for FY2025, 15.7% down from the prior year.
  • Share-based Compensation for Q4 2025 was $5.6 million at 4D Molecular Therapeutics, up from $4.5 million in the prior quarter.
  • The five-year high for Share-based Compensation was $7.6 million in Q4 2024, with the low at $2.3 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $4.9 million, with a median of $4.5 million recorded in 2022.
  • The sharpest move saw Share-based Compensation soared 267.98% in 2021, then plummeted 30.37% in 2025.
  • Over 5 years, Share-based Compensation stood at $3.7 million in 2021, then increased by 16.48% to $4.3 million in 2022, then skyrocketed by 36.06% to $5.9 million in 2023, then increased by 28.16% to $7.6 million in 2024, then dropped by 26.72% to $5.6 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $5.6 million, $4.5 million, and $5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.